Navigation Links
BioSpecifics Technologies Corp. to Host Conference Call to Report Third Quarter 2013 Financial Results on Tuesday, November 12, 2013
Date:11/5/2013

LYNBROOK, N.Y., Nov. 5, 2013 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® (collagenase clostridium histolyticum or CCH) in the U.S. and XIAPEX® in the EU, announced today that it will host a conference call and live audio webcast at 8:30 a.m. EST on Tuesday, November 12, 2013 to report its third quarter 2013 financial results and provide a corporate update.

In order to participate in the conference call, please dial 1-877-870-4263 (domestic) or 1-412-317-0790 (international). The live webcast can be accessed under "Events and Presentation" in the Investors section of the Company's website at www.biospecifics.com or you may use the link: http://www.videonewswire.com/event.asp?id=96458.

A replay of the call will be available one hour after the end of the conference on November 12, 2013 until 9:00 a.m. EST on November 23, 2013. To access the replay, please dial 1-877-344-7529 (domestic) or 1-412-317-0088 (international) and reference the access code 10035642. The archived webcast will be available for 90 days in the Investors section of BioSpecifics' website at www.biospecifics.com.

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications to date. Injectable collagenase is currently marketed as XIAFLEX® (collagenase clostridium histolyticum or CCH) in the U.S. for the treatment of adult Dupuytren's contracture patients with a palpable cord in the palm by BioSpecifics' partner, Auxilium Pharmaceuticals, Inc. (Auxilium), and Actelion has the marking rights in Canada. Under the Prescription Drug User Fee Act (PDUFA), the FDA has set an action date for CCH for the additional indication of Peyronie's disease of December 6, 2013. CCH is marketed by Swedish Orphan Biovitrum AB as XIAPEX® (the EU tradename for CCH) for the treatment of Dupuytren's contracture in 71 Eurasian and African countries. CCH is in clinical development for the treatment of several additional promising indications. Auxilium is testing CCH for frozen shoulder syndrome and expects to initiate next stage trials in the fourth quarter of 2013. Auxillium is also testing CCH as a treatment for cellulite in a Phase 2a study. BioSpecifics is currently managing the development of CCH for the treatment of human and canine lipomas, both of which are in Phase 2 trials, and expects to report top-line data from these trials by the end of 2013. For more information, please visit www.biospecifics.com.


'/>"/>
SOURCE BioSpecifics Technologies Corp.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. BioSpecifics Technologies Corp. Announces Partnership between Auxilium and Swedish Orphan Biovitrum AB for XIAPEX in Eurasia and Africa
2. BioSpecifics Technologies Corp. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
3. BioSpecifics Technologies Corp. Reports Third Quarter 2012 Financial Results
4. BioSpecifics Technologies Corp. To Present at UBS Global Life Sciences Conference
5. BioSpecifics Technologies Corp. Reports Second Quarter 2012 Financial Results
6. BioSpecifics Technologies Corp. Announces Presentations at Two Upcoming Investor Conferences in March
7. BioSpecifics Technologies Corp. Announces Appointment of George Gould to Board of Directors
8. BioStorage Technologies Selected to Provide Technical Consulting to Chinese National Genebank
9. Adaptive Biotechnologies Publishes Gold Standard Method for Sequencing Cells of the Adaptive Immune System
10. BCC Research Publishes a New Report On Global Markets for Rnai Technologies
11. Forensic Technologies and Services - 2013 Global Strategic Business Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... ... 2017 , ... Frederick Innovative Technology Center, Inc. (FITCI), a ... technology start-ups, is hosting “Celebration Friday” (a festive gathering highlighting client success stories) ... and networking at 3:30 p.m. at FITCI’s 4539 Metropolitan Court location, off English ...
(Date:4/20/2017)... ... ... USDM Life Sciences , the leading risk management, technological innovation and ... announce Holger Braemer as Vice President of its Europe division and Managing ... , Braemer is an integral part of USDM’s expansion of services and solutions for ...
(Date:4/20/2017)... ... April 20, 2017 , ... Parallel6™ , the leader in ... today that they were named one of the 2017 Top 10 eClinical Trial ... in the pharmaceutical industry. , “We take pride in honoring Parallel6 as one of ...
(Date:4/19/2017)... ... 2017 , ... The Vibrating Orifice Aerosol Generator (VOAG) was ... droplets of known diameters for research applications such as for calibrating droplet measuring ... monodisperse droplets. , The VOAG requires forcing liquid out of an orifice ...
Breaking Biology Technology:
(Date:3/24/2017)... -- The Controller General of Immigration from Maldives Mr. ... have received the prestigious international IAIR Award for the most innovative high ... ... Maldives Immigration Controller ... (small picture on the right) have received the IAIR award for the ...
(Date:3/22/2017)... Lithuania , March 21, 2017   ... and object recognition technologies, today announced the release ... kit (SDK), which provides improved facial recognition using ... cameras on a single computer. The new version ... to improve accuracy, and it utilizes a Graphing ...
(Date:3/20/2017)... Pa. , March 20, 2017 PMD ... 2.0 personal spirometer and Wellness Management System (WMS), a ... Founded in 2010, PMD Healthcare is a Medical ... with a mission dedicated to creating innovative solutions that ... life. With that intent focus, PMD developed the first ...
Breaking Biology News(10 mins):